Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Proton Pump Inhibitor/PPI
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
Gastroesophageal reflux (GER) is very common in children with cystic fibrosis (CF) and often those children have worse lung disease. Treating GER with acid blocker medications known as proton pump inhibitors (PPI) makes the stomach fluid less acidic so it does not damage the esophagus (food pipe). It is thought that changing the acidity of stomach fluid leads to different bacteria growing in the stomach which, when refluxed into the mouth and lungs, can cause infections. This study will study if PPIs change bacterial growth by compare bacterial cultures from stomach and lung fluid on children with CF who have GER. Throat cultures will be taken before starting the PPI and 3 months after.
3 Months - 21 Years
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.